Genfit S.A. (GNFT)
NASDAQ: GNFT · Real-Time Price · USD
4.310
-0.170 (-3.79%)
Nov 20, 2024, 4:00 PM EST - Market open
Genfit Revenue
Genfit had revenue of 61.10M EUR in the half year ending June 30, 2024, with 403.23% growth. This brings the company's revenue in the last twelve months to 80.47M, up 175.45% year-over-year. In the year 2023, Genfit had annual revenue of 34.48M with 31.38% growth.
Revenue (ttm)
80.47M EUR
Revenue Growth
+175.45%
P/S Ratio
n/a
Revenue / Employee
506,126 EUR
Employees
159
Market Cap
211.03M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 34.48M | 8.24M | 31.38% |
Dec 31, 2022 | 26.25M | -59.11M | -69.25% |
Dec 31, 2021 | 85.36M | 76.67M | 883.14% |
Dec 31, 2020 | 8.68M | -30.29M | -77.72% |
Dec 31, 2019 | 38.97M | 31.61M | 429.18% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ModivCare | 2.79B |
High Tide | 370.02M |
biote | 193.06M |
Sutro Biopharma | 160.96M |
MacroGenics | 141.33M |
SOPHiA GENETICS | 64.49M |
Utah Medical Products | 44.08M |
GNFT News
- 7 days ago - GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024 - GlobeNewsWire
- 13 days ago - GENFIT Reports Third Quarter 2024 Financial Information - GlobeNewsWire
- 2 months ago - Top 4 Health Care Stocks That May Keep You Up At Night - Benzinga
- 2 months ago - GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval - GlobeNewsWire
- 4 months ago - GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis - GlobeNewsWire
- 4 months ago - GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - GlobeNewsWire
- 5 months ago - GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH - GlobeNewsWire
- 5 months ago - GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis - GlobeNewsWire